ENLV Enlivex Ltd.
Price Chart
Executive Summary
Enlivex disclosed that its RAIN token holdings were valued at approximately $1.16 billion as of May 27, 2026, representing 79.57 billion tokens. The Rain Foundation also announced a $100 million liquidity commitment to the Rain protocol, positioning it as the third-largest prediction market protocol globally by TVL. This filing updates the company's treasury portfolio but provides no clinical or operational financial data.
Actionable Insight
The disclosed RAIN token valuation (~$1.16B) dwarfs Enlivex's $189M market cap, creating a potential arbitrage opportunity if the market re-rates the stock toward the treasury value. However, RAIN token liquidity and price volatility are key risks — monitor token price action and any future RAIN token sales or lock-up disclosures. The $100M liquidity commitment to Rain's protocol is a positive catalyst for the token's ecosystem credibility.
Key Facts
- Enlivex held 79,568,550,005 RAIN tokens valued at approximately $1.16 billion as of May 27, 2026.
- The Rain Foundation announced a $100 million liquidity commitment to Rain's prediction markets protocol.
- Rain protocol has over 29,000 users and has burned more than 100 million RAIN tokens through buyback-and-burn as of April 27, 2026.
- Rain is now the third-largest prediction market protocol globally by Total Value Locked (TVL), behind Polymarket (~$450M TVL).
- Five industry leaders were appointed to the Rain Foundation's advisory board.
- Enlivex's market cap is approximately $189 million, meaning the RAIN holdings value (~$1.16B) is over 6x the company's equity market cap.
Financial Impact
RAIN token holdings valued at approximately $1.16 billion, compared to Enlivex's $189M market cap, implying the treasury asset alone is worth ~6.1x the company's equity value.
Risk Factors
- RAIN token price is highly volatile and may not sustain the valuation used in the disclosure.
- The $1.16B valuation is based on a single date's market price; actual realizable value upon sale could be materially lower.
- Enlivex's clinical-stage biotech operations (Allocetra) have no approved products or disclosed revenue, adding fundamental risk.
- Historical performance shows prior ENLV reports have had negative T+20 outcomes, suggesting market skepticism toward such treasury updates.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-061765 |
| Document: ea0292428-6k_enlivex.htm | 0001213900-26-061765 |
| Document: 0001213900-26-061765-index-headers.html | 0001213900-26-061765 |
| Document: 0001213900-26-061765-index.html | 0001213900-26-061765 |
| Document: 0001213900-26-061765.txt | 0001213900-26-061765 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
12d ago
|
6-K
| $0.7640 $0.8500 | ▲ +11.26% | ▲ +11.30% | $0.7140 (−6.54%) |
|
May 27, 2026
13d ago
|
6-K
| $0.7820 $0.8500 | ▲ +8.70% | ▲ +7.49% | $0.7140 (−8.70%) |
|
May 18, 2026
22d ago
|
6-K
| $0.6970 $0.6840 | ▼ −1.87% | ▼ −3.48% | $0.7140 (+2.44%) |
|
May 15, 2026
25d ago
|
6-K
| $0.6970 $0.6840 | ▲ +1.87% | ▲ +3.48% | $0.7140 (−2.44%) |
|
Apr 30, 2026
5w ago
|
Press Release
| $0.8200 $0.8330 | ▲ +1.59% | ▼ −0.14% | $0.7140 (−12.93%) |
|
Apr 21, 2026
7w ago
|
PRESS-RELEASE / 6-K
| $0.8790 $0.8260 | ▼ −6.03% | ▼ −7.11% | $0.7140 (−18.77%) |
|
Apr 8, 2026
8w ago
|
6-K
| $0.9330 $0.8200 | ▼ −12.11% | ▼ −15.63% | $0.7140 (−23.47%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $1.10 $0.9300 | ▼ −15.45% | ▼ −15.03% | $0.7140 (−35.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access